Can a psychiatrist in Australia now legally prescribe psilocybin?

Yes, but only if the psychiatrist has applied for and been granted Authorised Prescriber status by the TGA, and only for the specific approved indication of treatment-resistant depression. It is not a general prescribing right available to all psychiatrists automatically.

What is the difference between psilocybin and psilocin?

Psilocybin is the compound found in fungi and is pharmacologically inactive until metabolised. After ingestion, the body converts it to psilocin by removing a phosphate group — a process called dephosphorylation. Psilocin is the active compound that crosses the blood-brain barrier and acts on serotonin receptors. Both compounds are scheduled under Australian law.

Did Australia become the first country to legalise psilocybin?

Some media coverage used that framing, but it requires qualification. Australia did not legalise psilocybin broadly. The TGA created a narrow clinical pathway allowing TGA-approved Authorised Prescriber psychiatrists to prescribe it for treatment-resistant depression from 1 July 2023. It remains a Schedule 9 prohibited substance for all other purposes. Several countries have clinical research frameworks; the Australian change was notable for creating a prescribing (rather than purely research) pathway.

Is there a reliable way to find an Authorised Prescriber for psilocybin in Australia?

The TGA maintains a public register of Authorised Prescribers. Patients seeking this pathway would need a referral to a psychiatrist who holds Authorised Prescriber approval for psilocybin, and would need to meet the clinical criteria for treatment-resistant depression. This page does not direct readers to specific practitioners or services — the TGA website (tga.gov.au) is the authoritative source for current regulatory information.

Psilocybin & Psychedelics in Australia: FAQ

By Tom Whitfield · 20 April 2026 · 9 min read

What Australians are actually asking about psilocybin

Three questions landed in our editorial inbox in the same week recently, all variations on: "Is psilocybin legal now?" The short version is: mostly no, with a narrow and specific exception since 2023. The details matter a lot, so I've tried to compile every question our readers have sent over the past year into one reference page.

A note on what this page does and doesn't do. I'm a health librarian, not a clinician. Nothing here is medical advice. I chase down primary sources for a living , I spent about forty minutes last Tuesday trying to locate an obscure 1970s pharmacology paper between birdwatching breaks, which is either dedication or a problem , and what I can offer is accurate, sourced information on classification, chemistry, regulation, and the state of research. That's the scope.

Legal status and scheduling

Q1. Is psilocybin legal in Australia?

Not for general use. Psilocybin is listed as a Schedule 9 Prohibited Substance under the Therapeutic Goods Administration's (TGA) Poisons Standard. Possession, supply, manufacture, or use outside a specific legal framework is a criminal offence under both Commonwealth and state/territory law.

The one exception: from 1 July 2023, the TGA amended the Poisons Standard to allow Authorised Prescribers , psychiatrists approved under the TGA's Authorised Prescriber pathway; to prescribe psilocybin (as a Schedule 8 controlled drug in that context) for treatment-resistant depression. That is a tightly regulated clinical pathway, not a general decriminalisation.

Q2. What changed in 2023?

The TGA made a formal rescheduling decision, effective 1 July 2023. Psilocybin moved from Schedule 9 prohibited to Schedule 8 Controlled Drug status only when prescribed by a TGA-approved Authorised Prescriber for treatment-resistant depression. Outside that clinical relationship, it remains Schedule 9. The decision followed a TGA review of published evidence and a public consultation period.

Q3. Can a GP prescribe psilocybin?

No. Only psychiatrists who have applied for and received Authorised Prescriber status from the TGA can prescribe psilocybin under the 2023 framework. General practitioners cannot prescribe it under standard prescribing rights.

Q4. Can I access psilocybin through the Special Access Scheme?

Prior to the Authorised Prescriber pathway opening, some patients could apply via the Special Access Scheme (SAS Category B). The TGA's guidance notes that the Authorised Prescriber pathway is now the primary route for approved clinical use. SAS applications are assessed individually and remain a separate regulatory mechanism. Neither pathway is available to the general public seeking recreational use.

Q5. What happens if I'm caught with psilocybin mushrooms?

That depends on your state or territory, but the consequences are serious. Under the Commonwealth Criminal Code and equivalent state legislation, psilocybin (and psilocin, the active metabolite) are prohibited substances. Penalties range from fines to imprisonment depending on quantity and jurisdiction. This page does not provide legal advice, consult a solicitor if you face a legal matter.

Q6. Is there any pathway for researchers to access psilocybin?

Yes. Researchers at approved institutions can apply for licences through the TGA and relevant state health departments to possess and use Schedule 9 substances for legitimate scientific research. This is a separate process from clinical prescribing and requires institutional ethics approval alongside regulatory permits.

Chemistry and pharmacology

Q7. What is psilocybin, chemically?

Psilocybin is a naturally occurring tryptamine alkaloid. Its chemical name is 4-phosphoryloxy-N,N-dimethyltryptamine. It's found in several species of fungi, most notably various Psilocybe species; and is structurally related to serotonin (5-hydroxytryptamine). After ingestion, it's rapidly dephosphorylated to psilocin, which is the pharmacologically active compound.

Q8. How does psilocin work in the brain?

Psilocin acts as a partial agonist at serotonin receptors, particularly the 5-HT_2A receptor, which is broadly expressed in the cortex. It also shows activity at other serotonin receptor subtypes. This mechanism is structurally distinct from cannabinoids, which act via the endocannabinoid system through receptors like CB1 and CB2. The two systems are different pharmacological targets entirely.

It's worth being precise here: the serotonergic mechanism is well described in pharmacology literature. What that mechanism means clinically, what it does or doesn't treat, is what's under active investigation. Those are separate questions.

Q9. Is psilocybin the same as LSD or MDMA?

No. All three are psychoactive substances classified as Schedule 9 prohibited (outside any narrow clinical exceptions), but their chemistry and receptor targets differ. LSD (lysergic acid diethylamide) is a semi-synthetic ergoline. MDMA is a phenethylamine. Psilocybin is a tryptamine. They share some serotonergic activity but are not the same compound and do not have identical pharmacological profiles.

Q10. What is psilocin's relationship to psilocybin?

Psilocybin is essentially a prodrug. After ingestion, intestinal and hepatic phosphatases cleave the phosphate group, converting it to psilocin. Psilocin is the compound that crosses the blood-brain barrier and binds serotonin receptors. When researchers measure pharmacokinetics in clinical studies, they are generally measuring psilocin plasma concentrations.

Q11. Are psilocybin mushrooms the only natural source?

No, though they are the most well-known. Psilocybin and related tryptamines have been identified in several fungal genera beyond Psilocybe. Some tryptamines also appear in certain plant species, though psilocybin itself is primarily a fungal compound. All natural sources containing psilocybin or psilocin are subject to the same Poisons Standard scheduling as the purified compound.

The research landscape

Q12. What kind of research has been done on psilocybin?

There is a growing body of published clinical research, primarily from institutions in the United States, United Kingdom, and Europe. Centres such as Johns Hopkins University's Center for Psychedelic and Consciousness Research and Imperial College London's Centre for Psychedelic Research have published peer-reviewed studies examining psilocybin in the context of treatment-resistant depression, major depressive disorder, and other conditions. Australian researchers, including groups at St Vincent's Hospital Melbourne, have also conducted and published clinical trials.

I'd note; and I think this is worth saying clearly, that many popular summaries of this research overstate both the effect sizes and the certainty of findings. Most trials to date are small, lack placebo controls that fully blind participants (difficult with a psychoactive substance), and have short follow-up periods. The published research is genuinely interesting; it is not yet settled science.

Q13. Has any psilocybin product been approved on the ARTG?

As of the information available at time of writing, no psilocybin product has received full registration on the ARTG (Australian Register of Therapeutic Goods). The Authorised Prescriber framework allows clinical use without full ARTG registration, under specific regulatory conditions set by the TGA.

Q14. What does "treatment-resistant depression" mean in this context?

The TGA's 2023 rescheduling decision specifically named "treatment-resistant depression" as the indication under which Authorised Prescribers may prescribe psilocybin. The clinical definition generally refers to depression that has not responded adequately to at least two different antidepressant treatments at adequate doses and durations. The specific criteria used in clinical assessments are a matter for prescribing psychiatrists to apply, not for this page to define.

Q15. Is there research on other conditions?

Published trials exist examining psilocybin across a range of areas including anxiety, addiction, and obsessive-compulsive disorder, among others. However, none of these indications currently carry regulatory approval in Australia. Describing the published research is not the same as describing approved therapeutic uses, those are legally and scientifically distinct categories.

Safety, risk, and related substances

Q16. What are the known risks associated with psilocybin?

Published literature describes several categories of risk. Acute psychological distress during an experience ("bad trips") is well documented. There are cardiovascular effects including temporary increases in blood pressure and heart rate. People with personal or family histories of psychotic disorders are considered at elevated risk of adverse psychological reactions. Hallucinogen persisting perception disorder (HPPD) is a rare but documented long-term adverse effect. Drug interactions, particularly with serotonergic medications, are a clinical concern. These risks are exactly why the substance sits inside a tightly controlled regulatory framework rather than being available over the counter.

Q17. Is psilocybin physically addictive?

Current pharmacological evidence suggests psilocybin does not produce physical dependence in the way opioids or alcohol do, and does not strongly stimulate dopamine-driven reward pathways associated with compulsive use. The Australian Drug Foundation's published information on psychedelics notes a low dependence potential compared to other scheduled substances. This does not mean it is without risk; psychological difficulties, including challenging experiences and exacerbation of pre-existing mental health conditions, remain documented concerns.

Q18. How does psilocybin compare to cannabis under Australian law?

Both are scheduled substances, but they sit at different points in the Poisons Standard. Medicinal cannabis products (those containing cannabidiol or THC) can be accessed via prescription under Schedule 4 or Schedule 8, with a broader prescriber base than psilocybin. Psilocybin's Authorised Prescriber requirement is more restrictive. Recreational use of both remains illegal across all Australian states and territories.

Q19. What about other psychedelics like ketamine or MDMA?

The TGA's 2023 amendment also rescheduled MDMA to Schedule 8 for use by Authorised Prescribers in the treatment of post-traumatic stress disorder (PTSD). Ketamine occupies a different scheduling position; it is a Schedule 8 controlled drug used in anaesthesia, and some clinics have been administering it for depression under existing prescribing frameworks, separate from the 2023 psychedelic amendments. Each substance has its own scheduling history, approved indications, and regulatory pathway. They should not be conflated.

Q20. Where can I find accurate, up-to-date information on the legal status?

The TGA's website (tga.gov.au) publishes the current Poisons Standard, all scheduling decisions, and guidance for Authorised Prescribers. The Australian Drug Foundation (adf.org.au) maintains accessible public-facing information on psychoactive substances. For legal questions specific to your state or territory, state health department websites and legal aid services are the appropriate resources. This page summarises publicly available information but is not a substitute for checking primary sources directly, which, frankly, is advice I'd give for almost any health or regulatory question.

Sources

, Tom Whitfield, Health librarian; references & fact-checking

Common questions

Is it legal to possess psilocybin mushrooms in Australia?: No. Psilocybin and psilocin are Schedule 9 prohibited substances under the TGA Poisons Standard. Possessing, supplying, or using them outside a TGA-approved clinical framework is a criminal offence under both Commonwealth and state/territory law. The 2023 rescheduling created a pathway for Authorised Prescribers only — it did not decriminalise possession for the general public.
Can a psychiatrist in Australia now legally prescribe psilocybin?: Yes, but only if the psychiatrist has applied for and been granted Authorised Prescriber status by the TGA, and only for the specific approved indication of treatment-resistant depression. It is not a general prescribing right available to all psychiatrists automatically.
What is the difference between psilocybin and psilocin?: Psilocybin is the compound found in fungi and is pharmacologically inactive until metabolised. After ingestion, the body converts it to psilocin by removing a phosphate group — a process called dephosphorylation. Psilocin is the active compound that crosses the blood-brain barrier and acts on serotonin receptors. Both compounds are scheduled under Australian law.
Did Australia become the first country to legalise psilocybin?: Some media coverage used that framing, but it requires qualification. Australia did not legalise psilocybin broadly. The TGA created a narrow clinical pathway allowing TGA-approved Authorised Prescriber psychiatrists to prescribe it for treatment-resistant depression from 1 July 2023. It remains a Schedule 9 prohibited substance for all other purposes. Several countries have clinical research frameworks; the Australian change was notable for creating a prescribing (rather than purely research) pathway.
Is there a reliable way to find an Authorised Prescriber for psilocybin in Australia?: The TGA maintains a public register of Authorised Prescribers. Patients seeking this pathway would need a referral to a psychiatrist who holds Authorised Prescriber approval for psilocybin, and would need to meet the clinical criteria for treatment-resistant depression. This page does not direct readers to specific practitioners or services — the TGA website (tga.gov.au) is the authoritative source for current regulatory information.